HIGH-YIELD STUDY GUIDE ACTUAL EXAM 2026/2027 - 100%
VERIFIED Q&A - PASS GUARANTEED - A+ GRADED
200 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply biopsychosocial theories to complex psychiatric presentations
2 Integrate pharmacologic and non-pharmacologic interventions for diverse populations
3 Evaluate evidence-based screening tools and diagnostic criteria
4 Analyze ethical and legal considerations in psychiatric practice
5 LMR Georgette PMHNP Board Exam Review PDF High
6 Yield Study Guide Actual Exam 2026
7 2027
8 100% Verified Q&A
9 Pass Guaranteed
10 A+ Graded
11 Foundations of Psychiatric-Mental Health Nurse Practitioner Board Review
12 Applied Psychiatric-Mental Health Nurse Practitioner Board Review
13 Advanced Psychiatric-Mental Health Nurse Practitioner Board Review
14 Psychiatric-Mental Health Nurse Practitioner Board Review Review
Page 1
,Q1 APPLY BIOPSYCHOSOCIAL THEORIES TO COMPLEX PSYCHIATRIC PRESENTATIONS
In the context of the dopamine hypothesis of schizophrenia, which finding most
directly challenges the traditional hyperdopaminergic model?
A. Antipsychotic efficacy correlates with D2 receptor occupancy in the striatum
B. Glutamatergic dysfunction can produce psychotic symptoms via cortical disinhibition
CORRECT
C. Dopamine release in the prefrontal cortex is reduced in negative symptoms
D. Stimulants can exacerbate positive symptoms in susceptible individuals
RATIONALE: The traditional model focuses on excess striatal dopamine, but the glutamate
hypothesis proposes that NMDA receptor hypofunction on cortical interneurons leads to
excessive glutamate release, causing psychosis. This challenges the exclusivity of dopamine
dysfunction. Options A and D support the dopamine model; C addresses regional dopamine but
doesn't challenge the hyperdopaminergic core.
Q2 APPLY BIOPSYCHOSOCIAL THEORIES TO COMPLEX PSYCHIATRIC PRESENTATIONS
A patient on fluoxetine for 6 weeks reports persistent insomnia and agitation.
Which pharmacogenetic finding would most likely explain this adverse effect
profile?
A. CYP2D6 ultra-rapid metabolizer phenotype
B. CYP2C19 poor metabolizer phenotype CORRECT
C. 5-HTTLPR long/long genotype
D. CYP3A4 inducer status
RATIONALE: Fluoxetine is a substrate of CYP2D6 and CYP2C19; a poor metabolizer at
CYP2C19 leads to elevated fluoxetine levels, increasing activation side effects like insomnia and
agitation. Ultra-rapid metabolism would lower levels. The 5-HTTLPR genotype influences
response but not drug levels. CYP3A4 induction would reduce levels.
Page 2
,Q3 APPLY BIOPSYCHOSOCIAL THEORIES TO COMPLEX PSYCHIATRIC PRESENTATIONS
In the context of the research domain criteria (RDoC) framework, which unit of
analysis is most directly associated with the 'negative valence systems' domain?
A. Resting-state functional connectivity of the default mode network
B. Amygdala hyperreactivity to threatening stimuli CORRECT
C. Dopamine D2 receptor binding in the ventral striatum
D. Gamma-aminobutyric acid (GABA) concentration in the anterior cingulate cortex
RATIONALE: RDoC's negative valence systems include responses to threat, loss, and frustrative
non-reward. Amygdala hyperreactivity is a key neural substrate for threat response. Default
mode connectivity relates to cognitive systems; dopamine binding relates to positive valence;
GABA relates to arousal/regulatory systems.
Q4 APPLY BIOPSYCHOSOCIAL THEORIES TO COMPLEX PSYCHIATRIC PRESENTATIONS
Which clinical scenario best exemplifies the 'double depression' concept?
A. Persistent depressive disorder with superimposed major depressive episodes CORRECT
B. Major depressive disorder with psychotic features
C. Bipolar II disorder with current hypomania
D. Disruptive mood dysregulation disorder with concurrent oppositional defiant disorder
RATIONALE: Double depression is the co-occurrence of persistent depressive disorder
(dysthymia) and major depressive episodes superimposed on it. This term specifically describes
this chronic plus acute pattern. The other options are distinct diagnostic entities not defined as
double depression.
Page 3
, Q5 APPLY BIOPSYCHOSOCIAL THEORIES TO COMPLEX PSYCHIATRIC PRESENTATIONS
A patient with generalized anxiety disorder has been on venlafaxine XR 225
mg/day for 8 weeks with partial response. Which augmentation strategy is most
evidence-based for this patient?
A. Adding pregabalin 300 mg/day
B. Adding buspirone 30 mg/day
C. Switching to paroxetine 40 mg/day
D. Adding quetiapine XR 150 mg/day CORRECT
RATIONALE: Quetiapine XR has FDA approval as adjunctive treatment for GAD, with evidence
from clinical trials. Pregabalin is effective but not FDA-approved for augmentation in GAD;
buspirone has limited evidence for augmentation; switching to another SSRI/SNRI is a
reasonable strategy but not specifically augmentation.
Q6 APPLY BIOPSYCHOSOCIAL THEORIES TO COMPLEX PSYCHIATRIC PRESENTATIONS
In the context of the Health Belief Model, which factor is most predictive of
medication adherence in a patient with schizophrenia?
A. Perceived severity of the illness
B. Perceived benefits of the medication CORRECT
C. Cues to action from healthcare providers
D. Perceived susceptibility to relapse
RATIONALE: Research on adherence in schizophrenia indicates that perceived benefits of
medication (e.g., symptom reduction) are a strong predictor of adherence. While other factors
matter, perceived benefits directly influence the cost-benefit analysis. Perceived severity and
susceptibility are important but less consistently predictive.
Page 4